CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porters Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. High adoption of stem cell technology
3.4.1.2. Emerging application of nanotechnology
3.4.1.3. Increasing prevalence of chronic diseases and trauma emergencies
3.4.1.4. Advancements in medical equipment technologies

3.4.2. Restraints

3.4.2.1. Ethical hurdles
3.4.2.2. Costly treatment associated with regenerative medicine

3.4.3. Opportunities

3.4.3.1. Lucrative opportunities of novel stem cell technologies
3.4.3.2. Increasing potential in emerging economies
3.4.3.3. Growing need of regenerative medicine in organ transplantation

CHAPTER 4: REGENERATIVE MEDICINE MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Cell Therapy

4.2.1. Key market trends
4.2.2. Key growth factors and growth opportunities
4.2.3. Market size and forecast

4.3. Gene Therapy

4.3.1. Key market trends
4.3.2. Key growth factors and growth opportunities
4.3.3. Market size and forecast

4.4. Tissue Engineering

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. Small Molecules And Biologics

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5: REGENERATIVE MEDICINE MARKET, BY MATERIAL

5.1. Overview

5.1.1. Market size and forecast

5.2. Synthetic Materials

5.2.1. Market size and forecast, by region
5.2.2. Market size and forecast, by type
5.2.3. Biodegradable synthetic polymers

5.2.3.1. Market size and forecast

5.2.4. Scaffold

5.2.4.1. Market size and forecast

5.2.5. Artificial vascular graft materials

5.2.5.1. Market size and forecast

5.2.6. Hydrogel material

5.2.6.1. Market size and forecast

5.3. Biologically Derived Materials

5.3.1. Market size and forecast, by region
5.3.2. Market size and forecast, by type
5.3.3. Collagen

5.3.3.1. Market size and forecast

5.3.4. Xenogeneic material

5.3.4.1. Market size and forecast

5.4. Genetically Engineered Materials

5.4.1. Market size and forecast, by region
5.4.2. Market size and forecast, by type
5.4.3. Deoxyribonucleic acid transfection vectors

5.4.3.1. Market size and forecast

5.4.4. Genetically manipulated cells

5.4.4.1. Market size and forecast

5.4.5. Three-dimensional polymer technology

5.4.5.1. Market size and forecast

5.4.6. Transgenics

5.4.6.1. Market size and forecast

5.4.7. Fibroblasts

5.4.7.1. Market size and forecast

5.4.8. Neural stem cells

5.4.8.1. Market size and forecast

5.4.9. Gene-activated matrices

5.4.9.1. Market size and forecast

5.5. Pharmaceuticals

5.5.1. Market size and forecast, by region
5.5.2. Market size and forecast, by type
5.5.3. Small molecules

5.5.3.1. Market size and forecast

5.5.4. Biologics

5.5.4.1. Market size and forecast

CHAPTER 6: REGENERATIVE MEDICINE MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Cardiovascular

6.2.1. Market size and forecast

6.3. Oncology

6.3.1. Market size and forecast

6.4. Dermatology

6.4.1. Market size and forecast

6.5. Musculoskeletal

6.5.1. Market size and forecast

6.6. Wound Healing

6.6.1. Market size and forecast

6.7. Ophthalmology

6.7.1. Market size and forecast

6.8. Neurology

6.8.1. Market size and forecast

6.9. Others

6.9.1. Market size and forecast

CHAPTER 7: REGENERATIVE MEDICINE MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by product type
7.2.4. Market size and forecast, by material
7.2.5. Market size and forecast, by application
7.2.6. Market size and forecast, by country

7.2.6.1. U.S. market size and forecast
7.2.6.2. Canada market size and forecast
7.2.6.3. Mexico market size and forecast

7.3. Europe

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by product type
7.3.4. Market size and forecast, by material
7.3.5. Market size and forecast, by application
7.3.6. Market size and forecast, by country

7.3.6.1. Germany market size and forecast
7.3.6.2. France market size and forecast
7.3.6.3. UK market size and forecast
7.3.6.4. Italy market size and forecast
7.3.6.5. Spain market size and forecast
7.3.6.6. Russia market size and forecast
7.3.6.7. Rest of Europe market size and forecast

7.4. Asia-Pacific

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by product type
7.4.4. Market size and forecast, by material
7.4.5. Market size and forecast, by application
7.4.6. Market size and forecast, by country

7.4.6.1. Japan market size and forecast
7.4.6.2. China market size and forecast
7.4.6.3. Australia market size and forecast
7.4.6.4. India market size and forecast
7.4.6.5. South Korea market size and forecast
7.4.6.6. Taiwan market size and forecast
7.4.6.7. Rest of Asia-Pacific market size and forecast

7.5. Lamea

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by product type
7.5.4. Market size and forecast, by material
7.5.5. Market size and forecast, by application
7.5.6. Market size and forecast, by country

7.5.6.1. Brazil market size and forecast
7.5.6.2. Turkey market size and forecast
7.5.6.3. Venezuela market size and forecast
7.5.6.4. Saudi Arabia market size and forecast
7.5.6.5. South Africa market size and forecast
7.5.6.6. Rest of LAMEA market size and forecast

CHAPTER 8: COMPANY PROFILES

8.1. Acelity Holdings, Inc. (Lifecell Corporation)

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Key strategic moves and developments

8.2. Athersys, Inc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. Cryolife, Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance

8.4. Integra Lifesciences Corporation

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. Isto Biologics (Isto Biologics Medical Systems, Inc.)

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Key strategic moves and developments

8.6. Medtronic Plc

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance

8.7. Organogenesis Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Key strategic moves and developments

8.8. Stryker Corporation

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. U.S. Stem Cell, Inc. (Bioheart, Inc.)

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. Zimmer Biomet Holdings, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments